Can mitral, tricuspid, aortic, and pulmonary regurgitation be caused by coronary artery disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Coronary Artery Disease Cause Valvular Regurgitation?

Coronary artery disease (CAD) can directly cause mitral and tricuspid regurgitation through ischemic mechanisms, but does not directly cause aortic or pulmonic regurgitation.

Mitral Regurgitation and CAD

CAD is a well-established cause of secondary (functional) mitral regurgitation through ischemic mechanisms 1, 2, 3. The pathophysiology involves:

  • Papillary muscle dysfunction or rupture from myocardial infarction
  • Left ventricular remodeling with wall motion abnormalities causing leaflet tethering
  • Annular dilation secondary to LV dysfunction
  • Restricted leaflet motion due to altered ventricular geometry

2 specifically addresses ischemic mitral regurgitation (IMR) as a common manifestation in patients with CAD, noting that the severity of IMR exerts a graded effect on survival—the greater the degree of IMR, the lower the survival. The mechanism is functional rather than structural valve disease, with the valve leaflets themselves being structurally normal 4, 3.

Clinical significance: Patients with CAD and reduced LV function commonly develop concomitant secondary mitral regurgitation 1. When moderate-to-severe MR accompanies CAD requiring revascularization, mitral valve repair should be considered during CABG, particularly with LVEF ≤35% 1, 5.

Tricuspid Regurgitation and CAD

CAD can cause functional tricuspid regurgitation through indirect mechanisms 6, 7:

  • Right ventricular dysfunction secondary to RV infarction
  • Pulmonary hypertension from left heart failure due to CAD
  • Tricuspid annular dilation from RV volume/pressure overload
  • RV remodeling in the setting of ischemic cardiomyopathy

6 documents cases of severe isolated tricuspid insufficiency in the setting of severe coronary disease with preserved left ventricular function, demonstrating that CAD can directly affect the right heart. 7 notes that TR is common in patients with ischemic mitral regurgitation, often developing as a consequence of the hemodynamic burden from left-sided disease.

Important caveat: Most TR in CAD patients is secondary and functional rather than organic valve disease. The tricuspid valve leaflets remain structurally normal, but regurgitation occurs due to annular dilation and altered RV geometry 4, 8.

Aortic Regurgitation and CAD

CAD does NOT directly cause aortic regurgitation. There is no mechanistic pathway by which coronary artery disease affects the aortic valve structure or function. The evidence provided contains no references linking CAD to AR 4, 1, 8, 9.

Aortic regurgitation results from:

  • Aortic valve leaflet abnormalities (bicuspid valve, degenerative disease)
  • Aortic root/ascending aorta pathology (dilation, dissection)
  • Endocarditis
  • Rheumatic disease

While patients with CAD may coincidentally have AR, this represents coexisting disease rather than a causal relationship.

Pulmonic Regurgitation and CAD

CAD does NOT directly cause pulmonic regurgitation. Similar to AR, there is no pathophysiologic mechanism linking coronary disease to pulmonic valve dysfunction 8, 9.

Pulmonic regurgitation typically results from:

  • Pulmonary hypertension (causing annular dilation)
  • Congenital heart disease (especially post-repair tetralogy of Fallot)
  • Endocarditis
  • Carcinoid syndrome

Exception: Severe pulmonary hypertension secondary to left heart failure from CAD could theoretically cause functional PR through annular dilation, but this would be an indirect effect through elevated pulmonary pressures rather than direct coronary disease.

Clinical Algorithm for Assessment

When evaluating valvular regurgitation in CAD patients:

  1. Mitral regurgitation: Assume ischemic/functional etiology until proven otherwise

    • Assess LV function, wall motion abnormalities, and leaflet tethering
    • Coronary angiography is recommended before valve surgery 1
    • Consider revascularization impact on MR severity
  2. Tricuspid regurgitation: Determine if secondary to RV dysfunction or pulmonary hypertension from left heart disease

    • Evaluate RV size/function and pulmonary pressures
    • Assess for RV infarction if acute presentation
  3. Aortic/pulmonic regurgitation: Search for alternative etiologies

    • These are NOT caused by CAD
    • Evaluate valve morphology and aortic/pulmonary artery dimensions
    • Consider separate pathologic processes

Critical pitfall: Do not attribute all valvular disease in CAD patients to ischemia. Only mitral and tricuspid regurgitation have established ischemic mechanisms. Aortic and pulmonic regurgitation require separate diagnostic evaluation 4, 1, 8.

References

Research

Severe isolated tricuspid insufficiency in coronary artery disease.

International journal of cardiology, 1987

Related Questions

What ICD-10 code diagnosis would be used for a patient with normal left ventricular systolic function, mitral valve thickening, tricuspid valve thickening, and mild residual regurgitation?
Should a patient with mild to moderate mitral valve regurgitation and mild tricuspid regurgitation be referred to cardiology?
What is the diagnosis for a patient with severe left and right atrial enlargement, mild to moderate mitral valve regurgitation, and trivial tricuspid regurgitation?
What is the best course of treatment for a patient with tricuspid regurgitation and mitral regurgitation, but normal echocardiogram results, including normal valve function and ejection fraction?
What is the diagnosis for a patient with normal aortic, mitral, and tricuspid valve structures, trivial mitral and tricuspid regurgitation, and no stenosis, with peak velocities of 1.7 m/s in the aortic valve, 1.2 m/s in the mitral valve, and 1.2 m/s in the tricuspid valve?
How should I manage a 30-year-old asymptomatic male with no comorbidities, no smoking or alcohol use, a family history of kidney disease, normal renal function, and isolated microscopic hematuria (6–8 red blood cells per high-power field)?
What are the recommended guidelines for deep vein thrombosis (DVT) prophylaxis in hospitalized adult or surgical patients?
What is the role of bosentan (endothelin‑receptor antagonist) in the management of interstitial lung disease (ILD) with pulmonary arterial hypertension (PAH)?
According to NCCN guidelines, how should a low‑grade appendiceal mucinous neoplasm (LAMN) be managed and surveilled?
What are possible causes of recurrent chest pain, pressure, and dizziness in a patient with negative cardiac testing (blood work, stress electrocardiogram, MRI) after alcohol consumption?
How should I manage a 23-year-old female with a normal thyroid-stimulating hormone (TSH) level (~2.4 µIU/mL) and an elevated total thyroxine (T4) level (~15.5 µg/dL)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.